Current Report Filing (8-k)
December 17 2020 - 12:44PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): December 17, 2020
Enzo
Biochem, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
New
York
(State
or Other Jurisdiction of Incorporation)
001-09974
|
|
13-2866202
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
527
Madison Avenue
|
|
|
New
York, New York
|
|
10022
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(212)
583-0100
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class
|
|
Trading
Symbol
|
|
Name
of Each Exchange on Which Registered
|
Common
Stock, $.01 par value
|
|
ENZ
|
|
The
New York Stock Exchange
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-1 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01
On
December 15, 2020, Enzo Biochem, Inc. (the “Company”) issued a press release titled “Enzo Biochem Hosting Key
Opinion Leader Call on GENFLEX™ Molecular System for COVID-19 and the Role of Testing in a Post-Vaccine Treatment Environment”
and related materials.
Item
7.01. Regulation FD Disclosure.
The
information provided in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference in its entirety.
The
information discussed under Item 8.01 above shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or incorporated by reference in any filing by the Company under the Securities Act of 1933,
as amended, except as shall be expressly set forth by specific reference in such a filing.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
|
ENZO
BIOCHEM, INC.
|
|
|
|
Date:
December 17, 2020
|
By:
|
/s/
David Bench
|
|
|
David
Bench
|
|
|
Chief
Financial Officer
|
2
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Jul 2023 to Jul 2024